Review
Gastroenterology & Hepatology
Annarosa Floreani, Sara De Martin
Summary: PSC is a chronic cholestatic liver disease with no effective treatment currently available. There is controversy over the use of UDCA in PSC treatment. Novel pharmacological strategies targeting bile composition, immunomodulation, gut microbiome, and fibrosis are emerging, suggesting potential for personalized combination therapies for successful PSC treatment.
DIGESTIVE AND LIVER DISEASE
(2021)
Article
Gastroenterology & Hepatology
Omar Y. Mousa, Brian D. Juran, Bryan M. McCauley, Mette N. Vesterhus, Trine Folseraas, Coleman T. Turgeon, Ahmad H. Ali, Erik M. Schlicht, Elizabeth J. Atkinson, Chang Hu, Denise Harnois, Elizabeth J. Carey, Andrea A. Gossard, Devin Oglesbee, John E. Eaton, Nicholas F. LaRusso, Gregory J. Gores, Tom H. Karlsen, Konstantinos N. Lazaridis
Summary: In patients with PSC, alterations in plasma BA consistent with cholestasis, UDCA treatment, and IBD were observed. BA profiles were able to predict future hepatic decompensation, demonstrating the clinical potential of BA profiling for use in clinical trials.
Article
Gastroenterology & Hepatology
Toshihiko Arizumi, Susumu Tazuma, Hiroyuki Isayama, Takahiro Nakazawa, Toshio Tsuyuguchi, Hajime Takikawa, Atsushi Tanaka
Summary: This study investigated the association between UDCA treatment and improved LT-free survival in a cohort of Japanese PSC patients.
JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Mark R. Deneau, Cara Mack, Douglas Mogul, Emily R. Perito, Pamela L. Valentino, Achiya Z. Amir, Matthew DiGuglielmo, Laura G. Draijer, Wael El-Matary, Katryn N. Furuya, Nitika Gupta, Jessica T. Hochberg, Simon Horslen, M. Kyle Jensen, Maureen M. Jonas, Nanda Kerkar, Bart G. P. Koot, Trevor J. Laborda, Christine K. Lee, Kathleen M. Loomes, Mercedes Martinez, Alexander Miethke, Tamir Miloh, Saeed Mohammad, Nadia Ovchinsky, Girish Rao, Amanda Ricciuto, Pushpa Sathya, Kathleen B. Schwarz, Uzma Shah, Ruchi Singh, Bernadette Vitola, Andreanne Zizzo, Stephen L. Guthery
Summary: The study analyzed the effects of oral vancomycin and ursodeoxycholic acid on children with primary sclerosing cholangitis, showing that these medications did not improve outcomes compared to no treatment, and patients progressed to end-stage liver disease at similar rates. Favorable outcomes were associated with mild disease phenotype and early disease stage.
Article
Gastroenterology & Hepatology
Karolina M. Wronka, Emil Bik, Piotr Milkiewicz
Summary: This study assessed the maternal and fetal outcomes of pregnancy in patients with primary sclerosing cholangitis (PSC). The results showed that pregnancy in PSC patients appears to be well tolerated, but requires close monitoring by an obstetrician and an experienced hepatologist.
DIGESTIVE AND LIVER DISEASE
(2022)
Article
Gastroenterology & Hepatology
European Assoc Study Liver
Summary: This article presents guidelines for the management of primary or secondary sclerosing cholangitis, covering topics such as diagnostic methods, prognostic assessment, early detection of complications, optimal care pathways, and therapeutic options for both adults and children.
JOURNAL OF HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Brian J. Wentworth, Rachita Khot, Stephen H. Caldwell
Summary: Primary sclerosing cholangitis (PSC) poses challenges in diagnosis, management, and progression due to its heterogeneity. Updated practice guidance by major liver disease associations addresses some of these challenges, but fails to thoroughly discuss daily clinical dilemmas. This review aims to delve into controversial topics including the use of ursodeoxycholic acid, normalization of alkaline phosphatase, consideration of PSC variants and mimickers, and the implications of continuous hepatobiliary malignancy screening. Of particular concern is the potential long-term adverse effects of repeated exposure to gadolinium-containing contrast in PSC patients who undergo frequent magnetic resonance imaging scans.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Review
Gastroenterology & Hepatology
Michal Prokopic, Ulrich Beuers
Summary: PSC is a rare liver disease characterized by bile duct abnormalities leading to liver fibrosis and potential cholangiocarcinoma. The exact pathogenesis is still unclear, with strong association with inflammatory bowel disease. Current medical treatments have not been proven effective, with liver transplantation remaining the most viable option for late-stage disease.
HEPATOLOGY INTERNATIONAL
(2021)
Article
Medicine, General & Internal
Anne-Christin Beatrice Wilde, Lena Maria Greverath, Lara Marleen Steinhagen, Nina Wald de Chamorro, Elise Leicht, Janett Fischer, Toni Herta, Thomas Berg, Beate Preuss, Reinhild Klein, Frank Tacke, Tobias Mueller
Summary: This study found that the prevalence of mAChR3inh+ auto-antibodies is significantly higher in both PBC and PSC patients. PBC patients with mAChR3inh+ auto-antibodies have higher levels of certain parameters and tend to have lower response rates to UDCA treatment. However, there are no significant differences in laboratory findings between PSC patients with and without mAChR3inh+ auto-antibodies.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Gastroenterology & Hepatology
Einar S. Bjornsson, Evangelos Kalaitzakis
Summary: PSC is a rare liver disease that often requires liver transplantation due to cirrhosis. There is currently no proven effective medical treatment, highlighting the urgent need in the medical field to find therapies that can alter the course of the disease.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2021)
Article
Gastroenterology & Hepatology
Bertus Eksteen, Christopher L. Bowlus, Aldo J. Montano-Loza, Eric Lefebvre, Laurent Fischer, Pamela Vig, Eduardo Bruno Martins, Jawad Ahmad, Kidist K. Yimam, Paul J. Pockros, Jordan J. Feld, Gerald Minuk, Cynthia Levy
Summary: After 24 weeks of CVC treatment, adults with PSC achieved a modest reduction in ALP levels, but did not meet the targets of ALP normalization or a 50% decrease. Most adverse events reported were mild to moderate.
HEPATOLOGY COMMUNICATIONS
(2021)
Review
Gastroenterology & Hepatology
Ilaria Lenci, Martina Milana, Alessandro Signorello, Giuseppe Grassi, Leonardo Baiocchi
Summary: The biliary tract is no longer considered as a passive system. Recent research has demonstrated the important role of biliary epithelia in bile formation. Bile acids, the most abundant organic molecules in bile, were initially seen as natural detergents but are now recognized as important signaling molecules. This review focuses on the effects of different bile acids on the biliary epithelia, particularly secondary bile acids derived from bacterial manipulation. Understanding the interaction between bile acids and cholangiocytes may contribute to better treatments for cholestatic diseases.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Editorial Material
Immunology
Shiv Pillai
Summary: Repeated doses of mRNA vaccines for COVID-19 result in an increase of IgG4 antibodies, which can neutralize the virus and form mixed immune complexes with IgG1. However, pure IgG4 may be less effective than IgG1 or IgG3 antibodies in facilitating opsonization and eliminating infected cells.
SCIENCE IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Dustin G. Shaw, Raul Aguirre-Gamboa, Marcos C. Vieira, Saideep Gona, Nicholas DiNardi, Anni Wang, Anne Dumaine, Jody Gelderloos-Arends, Zachary M. Earley, Katherine R. Meckel, Cezary Ciszewski, Anabella Castillo, Kelly Monroe, Joana Torres, Shailja C. Shah, Jean-Frederic Colombel, Steven Itzkowitz, Rodney Newberry, Russell D. Cohen, David T. Rubin, Christopher Quince, Sarah Cobey, Iris H. Jonkers, Christopher R. Weber, Joel Pekow, Patrick C. Wilson, Luis B. Barreiro, Bana Jabri
Summary: Multiomics analysis of right colon tissues identifies a distinct immune gene signature associated with greater risk of and shorter time to dysplasia in patients with primary sclerosing cholangitis, but not in patients with inflammatory bowel disease.
Article
Gastroenterology & Hepatology
Shekhar Singh Jadaun, Rohit Mehtani, Ana Hasnain, Sushant Bhatia, Vikash Moond, Mukesh Kumar, Vikash Kuhad, Shweta Singh, Shaleen Agarwal, Subhash Gupta, Sanjiv Saigal
Summary: This retrospective study analyzed the outcomes of living donor liver transplant (LDLT) in primary sclerosing cholangitis (PSC) at a tertiary liver transplant center in north India. The study found that LDLT in PSC can achieve good long-term outcomes, but there is a risk of PSC recurrence in approximately one-fifth of patients.
HEPATOLOGY INTERNATIONAL
(2023)
